Protalix BioTherapeutics
Plant-based Proteins with Improved Therapeutic Profiles
StartupProtalix BioTherapeutics is a Karmiel-based startup in the Health Tech & Life Sciences sector, established in 1994. Plant-based Proteins with Improved Therapeutic Profiles. The company has raised a total of $159.9M across 11 funding rounds, currently at the Public stage. Key investors include Psagot Investment House, More Investment House, Pfizer, among 5 total investors. The company has 51-200 employees. Core technologies: Biologicals, Molecules.
With $159.9M in total funding, Protalix BioTherapeutics is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released. The company holds 1 patent.
- StagePublic
- ProductReleased
- ModelB2B
- Employees51-200
- HQKarmiel
- DistrictNorth District
- Last Round$40M
- Psagot Investment House
- More Investment House
- Pfizer
5 investors total
155 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
www.pharmaceutical-technology.com,
www.biospace.com,
fabrydiseasenews.com.
What does Protalix BioTherapeutics do?
Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant-cell-based protein expression system. The company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix gained FDA approval for a plant-cell culture-expressed protein. Elelyso (taliglucerase alfa for injection) is the company's first drug product produced by ProCellEx. Elelyso was approved for marketing by the FDA in May 2012, soon followed by approval from multiple regulatory agencies including the EMA, Australian TGA, Brazilian ANVISA, and the Israeli Ministry of Health. The product has been licensed to Pfizer. The Protalix ProCellEx platform has the ability to manufacture complex proteins, antibodies, and vaccines and to orally deliver certain therapeutic proteins as demonstrated in animal models.
How much funding has Protalix BioTherapeutics raised?
Protalix BioTherapeutics has raised $159.9M in total funding across 11 rounds. The company is currently at the Public stage. Key investors include Psagot Investment House, More Investment House, Pfizer.
What sector is Protalix BioTherapeutics in?
Protalix BioTherapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Protalix BioTherapeutics located?
Protalix BioTherapeutics is based in Snunit St 2, Karmiel, Israel, North District.